Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic

[News]

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.

More... (http://www.news-medical.net/news/20150731/Eisai-Halozyme-partner-to-evaluate-eribulin-and-PEGPH20-in-HER2-negative-metastatic-breast-cancer.aspx)